WallStreetZenWallStreetZen

NASDAQ: ACRV
Acrivon Therapeutics Inc Stock Ownership - Who owns Acrivon Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Acrivon Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Mary MillerChief Legal Officer2025-10-01284$1.81
$514.04Sell
Peter BlumejensenPresident and CEO2025-08-2119,905$1.32
$26.27kSell
Erick GamelinChief Development Officer2025-08-14403$1.39
$560.17Sell
Katharine PetersonChief Accounting Officer2025-08-1499$1.39
$137.61Sell
Peter BlumejensenPresident and CEO2025-08-1459,766$1.39
$83.07kSell
Peter BlumejensenPresident and CEO2025-08-14490$1.39
$681.10Sell
Mary MillerChief Legal Officer2025-08-14184$1.39
$255.76Sell
Eric DevroeChief Operating Officer2025-08-14613$1.39
$852.07Sell
Adam D. LevyChief Financial Officer2025-08-011,164$1.26
$1.47kSell
Mary MillerChief Legal Officer2025-07-17558$1.32
$736.56Sell

1 of 4

ACRV insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ACRV insiders and whales buy or sell their stock.

ACRV Shareholders

What type of owners hold Acrivon Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ra Capital Management LP26.52%8,340,508$15.76MInstitution
Chione Ltd12.24%3,848,632$7.27MInsider
Kristina Masson11.73%3,691,232$6.98MInsider
Perceptive Advisors LLC9.87%3,104,139$5.87MInsider
Peter Blumejensen8.70%2,735,634$5.17MInsider
Sands Capital Alternatives LLC6.75%2,122,605$4.01MInstitution
Citadel Advisors LLC6.03%1,895,519$3.58MInstitution
Wellington Biomedical Innovation Master Investors Cayman I LP2.82%888,130$1.68MInsider
Wellington Management Group LLP2.82%888,130$1.68MInstitution
Vanguard Group Inc1.89%593,247$1.12MInstitution

1 of 3

ACRV vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ACRV54.52%45.48%Net SellingNet Selling
OSTX1.89%20.70%Net Selling
ANL0.05%0.00%
OTLK2.87%97.13%Net Buying
ESLA1.71%80.01%
View Top Biotech Stocks

Acrivon Therapeutics Stock Ownership FAQ

Who owns Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ: ACRV) is owned by 56.60% institutional shareholders, 47.22% Acrivon Therapeutics insiders, and 0.00% retail investors. Chione Ltd is the largest individual Acrivon Therapeutics shareholder, owning 3.85M shares representing 12.24% of the company. Chione Ltd's Acrivon Therapeutics shares are currently valued at $7.20M.

If you're new to stock investing, here's how to buy Acrivon Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.